搜索筛选:
搜索耗时2.3873秒,为你在为你在102,285,761篇论文里面共找到 8 篇相符的论文内容
发布年度:
Effects of Glucocorticoid?Induced Transcript 1 Gene Deficiency on Glucocorticoid Activation in Asthm
[期刊论文] 作者：Cheng-Ping Hu,Qiu-Fen Xun,Xiao,
来源：中华医学杂志（英文版） 年份：2018
Background: Glucocorticoid (GC) is the first?line therapy for asthma, but some asthmatics are insensitive to it. Glucocorticoid?induced transcript 1 gene (GLCCI...
Platelet Distribution Width on Admission Predicts In-Stent Restenosis in Patients with Coronary Arte
[期刊论文] 作者：Cheng-Ping Hu,Yu Du,Yong Zhu,C,
来源：中华医学杂志（英文版） 年份：2004
...
,Trichostatin A sensitizes cisplatin-resistant A549 cells to apoptosis by up-regulating death-associ
[期刊论文] 作者：Jun WU,Cheng-ping HU,Qi-hua GU,Ye-peng LI,Min SONG,
来源：中国药理学报（英文版） 年份：2010
...
[会议论文] 作者：Ling Qin,Xiao-ai Liu,Qian Xia,Cheng-ping Hu,Jun-tao Feng,
来源：中华医学会呼吸病学年会——2013第十四次全国呼吸病学学术会议 年份：2013
Objectives Respiratory syncytial virus (RSV) infection may cause a predisposition to the development of asthma from lots of epidemiological evidences.However, its mechanisms are incompletely understoo...
Overall survival (OS) with afatinib (A) vs gemcitabine/cisplatin (GC) in treatment-naive Chinese pat
[会议论文] 作者：Yi-Long Wu,Caicun Zhou,Cheng-Ping Hu,Jifeng Feng,Shun Lu,Yunchao Huang,Wei Li,Mei Hou,Jianhua Shi,Dan,
来源：第十七届全国临床肿瘤学大会暨2014年CSCO学术年会 年份：2014
...
Overall survival (OS) with afatinib (A) vs gemcitabine/cisplatin (GC) in treatment-naive Chinese pat
[会议论文] 作者：Yi-Long Wu,Caicun Zhou,Cheng-Ping Hu,Jifeng Feng,Shun Lu,Yunchao Huang,Wei Li,Mei Hou,Jianhua Shi,Dan,
来源：第十七届全国临床肿瘤学大会暨2014年CSCO学术年会 年份：2014
Objective:A, an oral, irreversible ErbB family blocker, was compared with GC in 364 Asian pts with EGFR mut positive NSCLC, including 327 pts from China.PFS was significantly prolonged with A vs GC in...
LUX-Lung 6: A randomized, open-label, Phase Ⅲ study of afatinib vs.gemcitabine/cisplatin as first-li
[会议论文] 作者：Yi-Long Wu,Sarayut L Geater,Cheng-Ping Hu,Jifeng Feng,Shun Lu,Yunchao Huang,Wei Li,Jian Hua Shi,Mei Hou,
来源：第十六届全国临床肿瘤学大会暨2013年CSCO学术年会 年份：2013
...
LUX-Lung 6: A randomized, open-label, Phase Ⅲ study of afatinib vs.gemcitabine/cisplatin as first-li
[会议论文] 作者：Yi-Long Wu,Sarayut L Geater,Cheng-Ping Hu,Jifeng Feng,Shun Lu,Yunchao Huang,Wei Li,Jian Hua Shi,Mei Hou,
来源：第十六届全国临床肿瘤学大会暨2013年CSCO学术年会 年份：2013
Background: Afatinib is an oral, irreversible, ErbB Family Blocker, blocking signaling from EGFR (ErbB1), HER2 (ErbB2) and ErbB4.Afatinib was superior to first-line pemetrexed/cisplatin in terms of pr...
相关搜索：
